{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:00:49Z","timestamp":1787061649109,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","award":["53\/2021"],"award-info":[{"award-number":["53\/2021"]}],"id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008050","name":"Fundaci\u00f3n Cellex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.medj.2023.07.006","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T10:34:51Z","timestamp":1691750091000},"page":"710-727.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1692-1125","authenticated-orcid":false,"given":"Alberto","family":"Hernando-Calvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vila-Casades\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacine","family":"Bareche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gonzalez-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnoosh","family":"Abbas-Aghababazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Lo Giacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatha","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Brana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vieito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haibe-Kains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Berche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Mirallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Saoudi","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"\u00c9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Carles","family":"Galceran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe L.","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nuciforo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Seoane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2023.07.006_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.07.006_bib2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic\u00a0squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2023.07.006_bib3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib4","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2021.39.15_suppl.2597","article-title":"Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with\u00a0unselected\u00a0\u201ccold\u201d tumors enrolled in\u00a0early\u00a0clinical trials (CT)","volume":"39","author":"Saavedra Santa Gadea","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/d41573-020-00204-y","article-title":"Combinations take centre stage in PD1\/PDL1 inhibitor clinical trials","volume":"20","author":"Upadhaya","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2023.07.006_bib7","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S1470-2045(20)30234-5","article-title":"Turning up the heat on non-immunoreactive tumours: opportunities for clinical development","volume":"21","author":"Ochoa de Olza","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib8","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2023.07.006_bib9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective Validation of a 21-Gene Expression Assay in Breast Cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N.\u00a0Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.medj.2023.07.006_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.07.006_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejca.2022.06.045","article-title":"Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials","volume":"173","author":"Salawu","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2023.07.006_bib12","first-page":"362","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"1979","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.medj.2023.07.006_bib13","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade Find the latest version : IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Murphy","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2023.07.006_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.medj.2023.07.006_bib15","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2023.07.006_bib16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/PO.19.00398","article-title":"Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials","volume":"4","author":"Dienstmann","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib17","doi-asserted-by":"crossref","first-page":"1708065","DOI":"10.1080\/2162402X.2019.1708065","article-title":"Expression of TIM3\/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1\/PDL1 resistance: implications of immunogram heterogeneity","volume":"9","author":"Kato","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2023.07.006_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T\u00a0cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.medj.2023.07.006_bib19","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.medj.2023.07.006_bib20","series-title":"Regular and young investigator award abstracts","first-page":"A239.1","article-title":"393 First-in-human phase 1\/2a study of the novel nonfucosylated anti\u2013CTLA-4 monoclonal antibody BMS-986218\u00a0\u00b1 nivolumab in advanced solid tumors: initial phase 1 results","author":"Friedman","year":"2020"},{"key":"10.1016\/j.medj.2023.07.006_bib21","article-title":"Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer","volume":"10","author":"Revenko","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.medj.2023.07.006_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/e23060759","article-title":"Silhouette Analysis for Performance Evaluation in Machine Learning with Applications to Clustering","volume":"23","author":"Shutaywi","year":"2021","journal-title":"Entropy"},{"key":"10.1016\/j.medj.2023.07.006_bib23","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/cancers12082283","article-title":"Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study","volume":"12","author":"Lombardi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2023.07.006_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","article-title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","volume":"171","author":"Even","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2023.07.006_bib25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.medj.2023.07.006_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","article-title":"Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy","volume":"19","author":"Bilen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.medj.2023.07.006_bib28","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0003-4975(00)01915-9","article-title":"Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma","volume":"70","author":"Yasunaga","year":"2000","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.medj.2023.07.006_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.medj.2023.07.006_bib30","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2023.07.006_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08830180902978120","article-title":"Molecular Mechanisms of IFN-\u03b3 to Up-Regulate MHC Class I Antigen Processing and Presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.medj.2023.07.006_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.dib.2022.108556","article-title":"Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1\/PD-L1 inhibitors","volume":"44","author":"Foy","year":"2022","journal-title":"Data Brief"},{"key":"10.1016\/j.medj.2023.07.006_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.medj.2023.07.006_bib34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41416-018-0220-9","article-title":"Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy","volume":"119","author":"Fumet","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2023.07.006_bib35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41598-019-57218-9","article-title":"Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Hwang","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2023.07.006_bib36","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2023.07.006_bib37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2023.07.006_bib38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2023.07.006_bib39","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2023.07.006_bib40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T\u00a0cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.medj.2023.07.006_bib41","first-page":"1","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"5951","author":"Miao","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.medj.2023.07.006_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002309","article-title":"Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis","volume":"14","author":"Snyder","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.medj.2023.07.006_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.medj.2023.07.006_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","article-title":"Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade","volume":"5","author":"Nathanson","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2023.07.006_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/1078-0432.CCR-21-1810","article-title":"High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer","volume":"28","author":"S\u00e1nchez-Guix\u00e9","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.07.006_bib46","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI128672","article-title":"A conserved intratumoral regulatory T\u00a0cell signature identifies 4-1BB as a pan-cancer target","volume":"130","author":"Freeman","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.medj.2023.07.006_bib47","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.abb4255","article-title":"Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic","volume":"369","author":"Chin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.medj.2023.07.006_bib48","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2022.40.16_suppl.2513","article-title":"A phase 1 trial of the bifunctional EGFR\/TGF\u03b2 fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors","volume":"40","author":"Bedard","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.07.006_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib51","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.medj.2023.07.006_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T\u00a0cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2023.07.006_bib53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s42003-021-02937-x","article-title":"Transcriptomic profiling of single circulating tumor cells provides insight into human metastatic gastric cancer","volume":"5","author":"Negishi","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.medj.2023.07.006_bib54","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2022.40.16_suppl.2512","article-title":"Phase I\/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with advanced tumors","volume":"40","author":"Guo","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib55","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/1078-0432.CCR-20-1163","article-title":"Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors","volume":"27","author":"Pender","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2023.07.006_bib56","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma","volume":"18","author":"Braun","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib57","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/annonc\/mdx647","article-title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade","volume":"29","author":"Nuciforo","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.medj.2023.07.006_bib59","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.medj.2023.07.006_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.medj.2023.07.006_bib61","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.medj.2023.07.006_bib62","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.annonc.2022.08.084","article-title":"Leveraging Big Data of Immune Checkpoint Blockade Response Identifies Novel Potential Targets","volume":"33","author":"Bareche","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2023.07.006_bib63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.medj.2023.07.006_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.medj.2023.07.006_bib65","series-title":"A Package for Survival Analysis in R. R Package Version 3.4-0","author":"Therneau","year":"2022"},{"key":"10.1016\/j.medj.2023.07.006_bib66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11121-013-0377-7","article-title":"Meta-Analysis and Subgroups","volume":"14","author":"Borenstein","year":"2013","journal-title":"Prev. Sci."},{"key":"10.1016\/j.medj.2023.07.006_bib67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2023.07.006_bib68","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/biom.12543","article-title":"Analysis : Reducing the Impact of Outlying Studies","volume":"73","author":"Lin","year":"2017","journal-title":"Biometrics"},{"key":"10.1016\/j.medj.2023.07.006_bib69","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/sim.4780101105","article-title":"A general parametric approach to the meta-analysis of randomized clinical trials","volume":"10","author":"Whitehead","year":"1991","journal-title":"Stat. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023002295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023002295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:57:04Z","timestamp":1763002624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634023002295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2666634023002295"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2023.07.006","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2023.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}